Imgt아이엠지티

Imgt is a small KONEX-listed medical device developer whose share price has fallen sharply over the past year, with no financial statements in the data to judge its earnings.

Imgt develops focused ultrasound devices, led by the IMD10 system used in ChemoSono Therapy for pancreatic cancer, and is preparing a multinational pivotal trial in the US and South Korea. The shares closed at ₩10,030, down 10% over one year and 24.5% over one month, with a market value of about ₩52.8B. The data contains no annual or trailing financials, so the business's current revenue and profitability cannot be assessed from it.

What stands out

• The share price is ₩10,030, well below its 52-week high of ₩28,000 but above the 52-week low of ₩8,690.
• No annual or trailing-twelve-month financials are in the data, and valuation multiples such as P/E and P/B are not available.
• Foreign ownership is 0% and 20-day investor flows are zero for foreign, institutional and retail groups in the data.
• Recent filings are mostly shareholder meetings, stock purchase option grants and investor relations events, with no results filings listed.
• No news headlines were found in the data for the period.

What to watch

• Whether the planned multinational pivotal trial for the IMD10 system in the US and South Korea progresses, as the company's main near-term milestone.
• Any upcoming financial statement filings, since none are included in the current data.
• Effects of the stock purchase option grants from September 2026 on existing shareholders, and the share price trend after the recent 24.5% one-month decline.